Peter de Boer
It is with regret that we mark the untimely passing of Peter de Boer on the 21 June 2020, following a short illness. Peter was a frequent participant at ECNP and a contributor to the Experimental Medicine Network. His death is a significant loss for the field.
Peter gained his Ph.D. in neuropharmacology at the University of Groningen in 1992, and held several academic positions, including a post-doctoral fellowship at the Centre for Molecular and Behavioral Neuroscience at Rutgers University in the United States.
Peter started his career in the pharmaceutical industry at Pharma Bio-Research, now PRA International, before joining Johnson & Johnson (Janssen Cilag BV) in 1999. After a short period at Syngenta Biopharma in UK, Peter joined the Janssen Neuroscience Experimental Medicine department, based in Beerse, Belgium, in 2005. During his time at Janssen, Peter contributed enormously to the discovery and development new molecular entities for psychiatric and neurodegenerative disorders including Spravato (Esketamine) and seltorexant.
Peter’s innovative approach in bridging clinical pharmacology, biomarkers and translational strategies combined with his encyclopedic knowledge of neurophysiology and neuropharmacology were remarkable traits, highly valued by all who worked with him.
As well as mourning the sudden loss of a dear and affectionate friend, all who knew Peter will miss a remarkable and humble individual of unfailing generosity and an exceptionally creative scientist, who made unique contributions to the field of neuropsychopharmacology.